Today: 19 April 2026
NVIDIA Corporation Faces Fresh Slurm Scrutiny After SchedMD Deal Raises AI Control Fears

NVIDIA Corporation Faces Fresh Slurm Scrutiny After SchedMD Deal Raises AI Control Fears

SAN FRANCISCO, April 7, 2026, 04:10 PDT

Nvidia Corp is under the microscope again after a Reuters piece spotlighted worries among AI and supercomputing pros that its acquisition of SchedMD might steer Slurm—the job-scheduling software widely used on large computing clusters—toward favoring Nvidia hardware. In response last week, Nvidia said its customers “benefit from our open source and free software” and pledged ongoing support and upgrades for Slurm for all users. Reuters

Slurm sits at the core of the system, handling the queuing, scheduling, and allocation of workloads across vast arrays of processors in AI and high-performance computing environments. That’s why the issue draws attention. After Nvidia disclosed its agreement in December, it stressed that Slurm would stay both open-source and vendor-neutral. SchedMD CEO Danny Auble described the acquisition as a way to “enhance the development of Slurm,” but emphasized it would remain open source. NVIDIA Blog

Nvidia’s position in the AI spending surge only raises the stakes. For the January quarter, sales soared 94% to $68.13 billion. The chipmaker is now projecting current-quarter revenue to hit $78 billion. Two customers—unnamed in the disclosure—made up 36% of fiscal 2026 sales. CEO Jensen Huang put it bluntly: “This new way of doing computing is not going to go back.” Reuters

With Nvidia’s dominance in AI hardware under scrutiny, customers and competitors are actively searching for other options. Broadcom on Monday announced a long-term deal with Google to build custom AI chips that runs through 2031. Reuters reports demand for Google’s tensor processing units, or TPUs, is picking up as companies look for ways around Nvidia’s more expensive graphics processors.

Back in December, Nvidia framed its SchedMD acquisition as a piece of its wider open-source move, with rivals circling. But as reported by Reuters, CUDA—Nvidia’s own software platform—still stands out as a key chip draw. The bottom line: software control can weigh about as heavily as the hardware.

That’s part of the reason a modest software acquisition has drawn attention well beyond the supercomputing crowd. Late last month, Reuters pointed out that Nvidia’s forward price-to-earnings ratio dropped to its lowest point since early 2019. Investors, the analysis noted, are uncertain whether the heavy AI infrastructure bets from Microsoft, Alphabet, and Amazon will actually translate into revenue and profit at the pace many had been counting on.

The deal isn’t one-dimensional. Nick Patience, who leads AI platforms at Futurum, noted that pulling SchedMD closer could help Nvidia streamline its tech stack. Still, there’s a risk: any step away from Slurm’s vendor-neutral roots might turn into an “optimized barrier” for rivals’ hardware, and that could spark pushback from open-source advocates. Futurum

At the start of trading Tuesday, Nvidia was holding steady near $177.64 a share, putting its market cap around $4.53 trillion. Investors are still letting the company chart its course, though questions hang over whether AI’s next phase depends more on chip speed, software dominance, or a mix.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

US Stock Market Today: Live Updates 07.04.2026

Hologic Buyout Nears Close After Final Approvals in Blackstone-TPG Deal; CEO Steve MacMillan to Retire
Next Story

Hologic Buyout Nears Close After Final Approvals in Blackstone-TPG Deal; CEO Steve MacMillan to Retire

Go toTop